Related Experiment Video

Updated: Apr 27, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Prognostic impact of ß-blocker use in patients with stable coronary artery disease

Christophe Bauters1, Gilles Lemesle1, Thibaud Meurice2

  • 1Centre Hospitalier Régional et Universitaire de Lille, Lille, France Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France Faculté de Médecine de Lille, Lille, France.

Heart (British Cardiac Society)
|June 21, 2014
PubMed

Insights

Beta-blocker use in stable coronary artery disease (CAD) patients was linked to reduced cardiovascular mortality. This observational study found a significantly lower risk of death from cardiovascular causes in patients taking beta-blockers.

Area of Science:

  • Cardiology
  • Pharmacology
  • Epidemiology

Background:

  • Stable coronary artery disease (CAD) is a significant cause of cardiovascular mortality.
  • Beta-blockers are commonly prescribed for CAD patients, but their impact on long-term mortality in stable disease requires further investigation.

Purpose of the Study:

  • To evaluate the association between beta-blocker use and cardiovascular mortality in a cohort of patients with stable coronary artery disease.
  • To determine if beta-blocker therapy influences long-term cardiovascular outcomes in this population.

Main Methods:

  • Prospective cohort study of 4184 outpatients with stable CAD.
  • Two propensity score analyses (cohort adjustment and matching) were used to control for confounding factors.
  • Cardiovascular mortality was assessed over a 2-year follow-up period.

Main Results:

  • Beta-blocker use was associated with younger age, hypertension, diabetes, and more severe CAD.
  • Propensity score adjustment showed a reduced hazard ratio (HR) for cardiovascular mortality (0.64; 0.42-0.98, p=0.04).
  • Propensity score matching (n=839 per group) revealed a significantly lower cardiovascular mortality rate in beta-blocker users (HR 0.43; 0.22-0.82, p=0.011).

Conclusions:

  • In patients with stable CAD, beta-blocker use is associated with a reduced risk of cardiovascular mortality.
  • These findings support the continued use of beta-blockers in managing stable coronary artery disease.
  • The observed benefit was consistent across various patient subgroups.
Abstract

Keywords:
Coronary Artery Disease

More Related Videos

The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

27.2K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K